Research programme: reproductive health and immunology therapeutics - Santhera/Serono

Drug Profile

Research programme: reproductive health and immunology therapeutics - Santhera/Serono

Alternative Names: Reproductive health and immunology therapeutics research programme - Santhera/Serono

Latest Information Update: 12 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono; Santhera Pharmaceuticals
  • Developer Santhera Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Immunological disorders; Infertility

Most Recent Events

  • 12 Mar 2008 Discontinued - Preclinical for Immunological disorders in Germany (unspecified route)
  • 12 Mar 2008 Discontinued - Preclinical for Infertility in Germany (unspecified route)
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top